Harley-Davidson Inc vs Repligen Corporation Common Stock — how do they compare? Harley-Davidson Inc trades at $26.92 (market cap $2.86B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.9× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.73% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Repligen Corporation Common Stock for 0 Days on average.
| HOG | RGEN | |
|---|---|---|
Market Cap | $2.86B | $11.14B |
Volume | 1,391,703 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $194.57 |
52-Week Low | $17.19 | $102.87 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $3.27B | $11.02B |
Dividend Yield | 2.73% | — |
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.96, down 1.5% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 EPS beat ($0.75 actual vs. $0.645 expected) but missed in Q4 2025 and Q1 2026. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 4.78%. Recent news highlights tariff risks and a data breach investigation, while analyst consensus is a $28.50 price target with a Hold-heavy rating.
The outlook is cautious; HOG faces revenue pressure and margin compression, offset by low valuation multiples (P/E 15.26, P/S 0.74) and a dividend. Key risks include competitive threats, tariff exposure, and economic sensitivity. Upside depends on execution of the 'Back to the Bricks' plan stabilizing sales, but investor sentiment remains neutral amid institutional selling and mixed earnings trends.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →